Advertisement

Opioid Agonist Diversion in Opioid-Dependence Treatment

  • Hannu Alho
Reference work entry

Abstract

Diversion is defined in this publication as unauthorized rerouting or use of a substance, and abuse is defined as any use of a prescription drug that deviates from medical practice. This refers to the manner in which medication is used such as snorting, injecting, taking excessive quantities, or combining it with other substances for intoxicative purposes.

Diversion and abuse of pharmacotherapy used in opioid-dependence treatment can have a serious negative impact on public health at the individual and societal level. Diversion can lower the credits of treatment services through increased morbidity and mortality and economic burden through lost productivity and unemployment. Diversion is a global problem, but most studies and concerns arise from the USA, Australia, and Northern Europe. While existing evidence confirms the occurrence of this issue, standardized indicators are missing and the phenomenon is not uniformly appreciated by prescribers and policy makers.

Most publications of diversion and abuse report the mortality rates associated with the diversion and abuse of methadone and prescription opioid analgesics. The reports of fewer buprenorphine-related deaths compared with deaths associated with methadone can be attributed to buprenorphine’s pharmacology and ceiling effect on respiratory depression. However, deaths due to asphyxia as well as following acute poisoning with severe respiratory depression have recently been attributed to buprenorphine in opioid abusers. The abuse prevalence and injection of buprenorphine tablets are reported in worldwide publications addressing the harms associated with it. Several studies indicate that inability to enter opioid maintenance or substitution treatment could be a significant contributor to diversion. In addition, studies are challenging the often-held view that regulation and restricted access are necessary to ensure the safety of individuals using opioid agonists’ medications.

To lower the diversion and develop strategies to avoid abuse, it is important therefore to examine and understand the reasons of it. One of the most important strategies to avoid diversion is good quality of the treatment and treatment outcomes. Some pharmacotherapies may have lover diversion potentiality, but the key factor is patient confidentiality and good quality of treatment.

Keywords

Infective Endocarditis Opioid Dependence Fatal Overdose Agonist Opioid Treatment Overdose Mortality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aitken CK, Higgs PG, Hellard ME (2008) Buprenorphine injection in Melbourne, Australia – an update. Drug Alcohol Rev 27:197–199PubMedCrossRefGoogle Scholar
  2. Alhaddad H, Cisternino S, Declèves X et al (2013) Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Br J Anaesth 110(5):842. doi:10.1093/bja/aet082PubMedGoogle Scholar
  3. Alho H, Sinclair D, Vuori E, Holopainen A (2007) Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88:75–78PubMedCrossRefGoogle Scholar
  4. Altice FL, Bruce RD, Lucas GM et al (2011) HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 56(Suppl 1):S22–S32PubMedCentralPubMedCrossRefGoogle Scholar
  5. American psychiatric Association (2001) Diagnostic and statistical manual of mental disorders, 4th Edition, Text Revision (DSM-IV-TR). American Psychiatric Publishing, Arlington, USAGoogle Scholar
  6. American Psychiatric Association (2004) Diagnostic and statistical manual of mental disorders (DSM-IV)Google Scholar
  7. Auriacombe M, Franques P, Tignol J (2001) Deaths attributable to methadone vs buprenorphine in France. JAMA: J Am Med Assoc 285:45CrossRefGoogle Scholar
  8. Australian drug trends: findings of the illicit drug reporting system and the ecstasy and related drugs reporting system. Last updated on 13/07/2009. http://www.aic.gov.au/crime_types/drugs_alcohol/illicit_drugs/ndarc_adt.aspx
  9. Bacha J, Reast S, Pearlstone A (2010) Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl 12:9–19Google Scholar
  10. Beer B, Rabl W, Libiseller K et al (2010) Impact of slow-release oral morphine on drug abusing habits in Austria. Neuropsychiatry 24:108–117Google Scholar
  11. Bell J (2010) The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician’s perspective. Addiction 105:1531–1537PubMedCrossRefGoogle Scholar
  12. Bell JR, Butler B, Lawrance A et al (2009) Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 104:73–77PubMedCrossRefGoogle Scholar
  13. Berson A, Gervais A, Cazals D et al (2001) Hepatitis after intravenous buprenorphine abuse in heroin addicts. J Hepatol 34:346–350PubMedCrossRefGoogle Scholar
  14. Cami J, Farre M (2003) Drug addiction. N Engl J Med 349:975–986PubMedCrossRefGoogle Scholar
  15. Center for Disease Control and Prevention (2011) HIV Strategic Plan 2011 through 2015 (Division of HIV/AIDS Prevention). www.cdc.gov/hiv/pdf/policies_DHAP-strategic-plan.pdf
  16. Center for Disease Control and Prevention (2004) HIV prevention strategic plan through 2005. CDC. www.cdc.giv/hiv/resources/reports/psp/pdf/prev-strat-plan.pdf
  17. Center for Disease Control and Prevention (2010) Emergency department visits involving nonmedical use of selected prescription drugs – United States, 2004–2008. Morb Mortal Wkly Rep 59:705–735Google Scholar
  18. Chong E, Poh KK, Shen L et al (2009) Infective endocarditis secondary to intravenous subutex abuse. Singap Med J 50:34–42Google Scholar
  19. Courty P (2009) Use and abuse of high-dose buprenorphine (HDB) obtained without a prescription: a French survey. Heroin Addict Relat Clin Probl 11:23–30Google Scholar
  20. Dasgupta N, Bailey EJ, Cicero T et al (2010) Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med 11:1078–1091PubMedCrossRefGoogle Scholar
  21. De Maeyer J, Vanderplasschen W, Broekaert E (2010) Quality of life among opiate-dependent individuals: a review of the literature. Int J Drug Policy 21:364–380PubMedCrossRefGoogle Scholar
  22. Degenhardt L, Larance BK, Bell JR et al (2009) Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust 191:161–165PubMedGoogle Scholar
  23. Degenhardt L, Bucello C, Mathers B et al (2011) Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 106:32–51PubMedCrossRefGoogle Scholar
  24. Drug Abuse Warning Network (2011) Last updated on 14/09/2011. http://www.samhsa.gov/data/DAWN.aspx
  25. Fiellin DA, O’Connor PG (2002) New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 137:688–692PubMedCrossRefGoogle Scholar
  26. Gibson AE, Degenhardt LJ (2007) Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 26:405–410PubMedCrossRefGoogle Scholar
  27. Goldstein A, Herrera J (1995) Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 40:139–150PubMedCrossRefGoogle Scholar
  28. Hansen RN, Oster G, Edelsberg J et al (2011) Economic costs of nonmedical use of prescription opioids. Clin J Pain 27:194–202PubMedCrossRefGoogle Scholar
  29. Havens JR, Walker R, Leukefeld CG (2007) Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend 87:98–102PubMedCrossRefGoogle Scholar
  30. Ho RC, Ho EC, Mak A (2009a) Cutaneous complications among i.v. buprenorphine users. J Dermatol 36:22–29PubMedCrossRefGoogle Scholar
  31. Ho RC, Ho EC, Tan CH, Mak A (2009b) Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse 35:199–202PubMedCrossRefGoogle Scholar
  32. International Narcotics Control Board (2011) Annual report. https://www.incb.org/documents/Publications/AnnualReports/AR2011/AR_2011_English.pdf
  33. Jenkinson RA, Clark NC, Fry CL, Dobbin M (2005) Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 100:197–205PubMedCrossRefGoogle Scholar
  34. Kim HK, Smiddy M, Hoffman RS et al (2012) Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics 130(6):e1700–e1703PubMedCrossRefGoogle Scholar
  35. Kimber J, Copeland L, Hickman M et al (2010) Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 341:c3172PubMedCentralPubMedCrossRefGoogle Scholar
  36. Laberke PJ, Bartsch C (2010) Trends in methadone-related deaths in Zurich. Int J Legal Med 124:381–385PubMedCrossRefGoogle Scholar
  37. Larance B, Ambekar A, Azim T et al (2011) The availability, diversion and injection of pharmaceutical opioids in South Asia. Drug Alcohol Rev 30:246–254PubMedCrossRefGoogle Scholar
  38. Merriam–Webster’s Dictionary of Law (1996) Merriam–Webster, Inc.Google Scholar
  39. Montesano F, Zaccone D, Battaglia E et al (2010) Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre. Clin Drug Investig 30(Suppl 1):13–19PubMedCrossRefGoogle Scholar
  40. Noroozi A, Mianji F (2008) Singapore’s experience with buprenorphine (Subutex). Iran J Psychiatry Behav 2:54–59Google Scholar
  41. O’Brien CP (1996) Drug addiction and drug abuse. In: Hardman JG et al (eds) Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hil, New York, pp 557–577Google Scholar
  42. Okie S (2010) A flood of opioids, a rising tide of deaths. N Engl J Med 363:1981–1985PubMedCrossRefGoogle Scholar
  43. Perret G, Deglon JJ, Kreek MJ et al (2000) Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction 95:1647–1653PubMedCrossRefGoogle Scholar
  44. Rainey HB (1986) Abuse of buprenorphine. N Z Med J 99:72PubMedGoogle Scholar
  45. Reynaud M, Petit G, Potard D, Courty P (1998) Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93:1385–1392PubMedCrossRefGoogle Scholar
  46. Simojoki K, Alho H (2008) Finnish experience with buprenorphine-naloxone combination (Suboxone®): survey evaluations with intravenous drug users. Heroin Addict Relat Clin Probl 10:33–36Google Scholar
  47. Simojoki K, Alho H (2013) A five-year follow-up of buprenorphine abuse potential. J Alcohol Drug Depend 1:2. doi:10.4172/jaldd.1000111Google Scholar
  48. Subata E, Gilman M, Alho H et al (2013) Recommendations for measuring treatment outcomes in opioid dependence management: consensus from the GLADD meeting. Heroin Addict Relat Clin Probl 15(3):55–60Google Scholar
  49. Wickert C, Thane K, Reimer J (2009) Abuse of substitution medication from the user’s perspective – motivation, prevalence and consequences. Suchtmedizin 11:182Google Scholar
  50. Winstock AR, Lea T, Sheridan J (2008) Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy 19:450–458PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  1. 1.Institute of Clinical Medicine, Department of MedicineUniversity of HelsinkiHelsinkiFinland

Personalised recommendations